Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of <i>Helicobacter pylori</i> in duodenal ulcer patients in Asia and Africa
抄録
<jats:sec><jats:title>Background:</jats:title><jats:p>Studies assessing the efficacy of triple therapy containing clarithromycin and amoxicillin for the eradication of <jats:italic>Helicobacter pylori</jats:italic> infection and healing of duodenal ulcers in Asian and African countries are limited.</jats:p></jats:sec><jats:sec><jats:title>Aim:</jats:title><jats:p>To determine the efficacy and safety of 1‐week triple therapy with omeprazole, amoxicillin and clarithromycin for eradicating <jats:italic>H. pylori</jats:italic> infection in patients with active duodenal ulcer living in Asian and African regions.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>This was an open‐label, multicentre study in 11 centres in Asia and Africa. Patients with endoscopy‐proven duodenal ulcer and who were <jats:italic>H. pylori</jats:italic>‐positive were treated with clarithromycin 500 mg, omeprazole 20 mg, and amoxicillin 1000 mg, all given twice daily for 7 days. Upper endoscopy was repeated at week 6 to check for ulcer healing and <jats:italic>H. pylori</jats:italic> status.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>A total of 117 patients were recruited. <jats:italic>H. pylori</jats:italic> eradication rates were 85% by per protocol analysis and 80% by intention‐to‐treat analysis. Ulcer healing was found in 94% of subjects (per protocol analysis). Clinical success, measured by change of pre‐treatment ulcer symptoms, was strongly supported by complete resolution or improvement in 100% of the evaluable patients (per protocol analysis). Since treatment‐related adverse events, when present, were largely mild or moderate, the triple therapy regimen was considered safe.</jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p>Seven‐day triple therapy with omeprazole, amoxicillin, and clarithromycin was efficacious for treating Asian and African patients with duodenal ulcer disease associated with <jats:italic>H. pylori</jats:italic> infection, and the treatment regimen was well‐tolerated.</jats:p></jats:sec>
収録刊行物
-
- Alimentary Pharmacology & Therapeutics
-
Alimentary Pharmacology & Therapeutics 14 (11), 1529-1535, 2000-11-27
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360298761266570112
-
- NII論文ID
- 30004880957
-
- ISSN
- 13652036
- 02692813
-
- データソース種別
-
- Crossref
- CiNii Articles